Publicerat: 2023-05-15 10:44:30

Inhalation Sciences: Rights issue outcome - Redeye

Redeye comments on ISAB’s rights issue outcome, which was subscribed to approximately 23% in total. However, as the rights issue was guaranteed up to 80%, the company receives around SEK13.7m before issue-relating costs (cSEK3.5m). As we already anticipated a capital raising, the outcome does not render any changes in our fair value range with a base case of SEK17.

Länk till analysen

Läs mer om Inhalation Sciences Sweden AB